Serum insulin-like growth factor binding protein 3 as a promising diagnostic and prognostic biomarker in esophagogastric junction adenocarcinoma.
Serum insulin-like growth factor binding protein 3 as a promising diagnostic and prognostic biomarker in esophagogastric junction adenocarcinoma.
复制标题
DOI：
10.1007/s12672-022-00591-1
复制
发表时间：
2022-11-21
影响因子：
2.2
通讯作者：
Wu, Fang-Cai
中科院分区：
文献类型：
--
作者：
Ding, Tian-Yan;Peng, Yu-Hui;Hong, Chao-Qun;Huang, Bin-Liang;Liu, Can-Tong;Luo, Yun;Chu, Ling-Yu;Zhang, Biao;Li, Xin-Hao;Qu, Qi-Qi;Xu, Yi-Wei;Wu, Fang-Cai
食管胃结合部腺癌（EJA）缺乏血清生物标志物来协助诊断和预后。在这里，我们的目的是评估血清胰岛素样生长因子结合蛋白 3 (IGFBP3) 在 EJA 患者中的诊断和预后价值。 2016年11月至2020年1月招募了320名参与者，他们被随机分为训练队列（112名正常对照和102名EJA患者，包括24名早期患者）和验证队列（56名正常对照和50名EJA患者，包括12名早期患者）。我们使用受试者工作特征曲线（ROC）来评估诊断价值。列线图的预测性能通过一致性指数（C 指数）进行评估。早期EJA或EJA患者血清IGFBP3水平显着低于对照组（P<0.01）。血清 IGFBP3 的测量结果显示，训练队列中的曲线下面积为 0.819，特异性为 90.18%，敏感性为 43.14%。在验证队列中观察到类似的结果（0.804、87.50%、42.00%）。重要的是，血清 IGFBP3 对早期 EJA 具有令人满意的诊断价值（训练组和验证组分别为 0.822、90.18%、45.83% 和 0.811、84.48%、50.00%）。此外，生存分析表明较低的血清IGFBP3水平与不良预后相关（P<0.05）。 Cox多变量分析显示血清IGFBP3是独立的预后因素（HR = 0.468，P = 0.005）。与TNM分期相比，基于血清IGFBP3、肿瘤大小和TNM分期的列线图表明预后预测的C指数有所改善（0.625 vs. 0.735，P = 0.001）。我们发现血清 IGFBP3 是 EJA 的潜在诊断和预后标志物。同时，列线图可以更准确、更有效地预测EJA的预后。在线版本包含可在 10.1007/s12672-022-00591-1 获取的补充材料。
Esophagogastric junction adenocarcinoma (EJA) lacks serum biomarkers to assist in diagnosis and prognosis. Here, we aimed to evaluate the diagnostic and prognostic value of serum insulin-like growth factor binding protein 3 (IGFBP3) in EJA patients. 320 participants were recruited from November 2016 to January 2020, who were randomly divided into a training cohort (112 normal controls and 102 EJA patients including 24 early-stage patients) and a validation cohort (56 normal controls and 50 EJA patients including 12 early-stage patients). We used receiver operating characteristics curve (ROC) to evaluate diagnostic value. The predictive performance of the nomogram was evaluated by the concordance index (C-index). Serum IGFBP3 levels were significantly lower in early-stage EJA or EJA patients than those in controls (P < 0.01). Measurement of serum IGFBP3 demonstrated an area under curve of 0.819, specificity 90.18% and sensitivity 43.14% in training cohort. Similar results were observed in validation cohort (0.804, 87.50%, 42.00%). Importantly, serum IGFBP3 had a satisfactory diagnostic value for early-stage EJA (0.822, 90.18%, 45.83% and 0.811, 84.48%, 50.00% in training and validation cohorts, respectively). Furthermore, survival analysis demonstrated that lower serum IGFBP3 level was related to poor prognosis (P < 0.05). Cox multivariate analysis revealed that serum IGFBP3 was an independent prognostic factor (HR = 0.468, P = 0.005). Compared with TNM stage, a nomogram based on serum IGFBP3, tumor size and TNM stage indicated an improved C-index in prognostic prediction (0.625 vs. 0.735, P = 0.001). We found that serum IGFBP3 was a potential diagnostic and prognostic marker of EJA. Meanwhile, the nomogram might predict the prognosis of EJA more accurately and efficiently. The online version contains supplementary material available at 10.1007/s12672-022-00591-1.
登录
查看更多内容
DOI：
10.1002/hep.29561
发表时间：
2018-03
期刊：
Hepatology (Baltimore, Md.)
影响因子：
--
作者：
Luo P;Yin P;Hua R;Tan Y;Li Z;Qiu G;Yin Z;Xie X;Wang X;Chen W;Zhou L;Wang X;Li Y;Chen H;Gao L;Lu X;Wu T;Wang H;Niu J;Xu G
通讯作者：
Xu G
影响因子：
1
作者：
Pepe MS;Fan J;Feng Z;Gerds T;Hilden J
通讯作者：
Hilden J
影响因子：
5
作者：
Kucera, Radek;Topolcan, Ondrej;Fuchsova, Radka
通讯作者：
Fuchsova, Radka
DOI：
10.1111/j.1440-1746.2008.05572.x
发表时间：
2008-11-01
影响因子：
4.1
作者：
Kusano, Chika;Gotoda, Takuji;Shimoda, Tadakazu
通讯作者：
Shimoda, Tadakazu
影响因子：
7.4
作者：
通讯作者：
--